GPCR Stock Risk & Deep Value Analysis
Structure Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on GPCR
We analyzed Structure Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GPCR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when GPCR moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈GPCR Performance Overview3yr weekly
Unlock GPCR Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
GPCR Quality Rating
GPCR Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Structure Therapeutics Inc (GPCR)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
mid
Market Cap
$3.75B
GPCR Deep Value Analysis
GPCR Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
GPCR Red Flags & Warning Signs
- ⚠
Negative or inconclusive Phase 2b data for GSBR-1290
- ⚠
Significant clinical delays or regulatory hurdles
- ⚠
Increased competitive pressure from other oral GLP-1 programs
Unlock GPCR Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
GPCR Financial Health Metrics
Market Cap
$3.75B
P/E Ratio
-66.96
Profit Margin
0.00%
Debt-to-Equity
0.05
Dividend Yield
0.00%
Beta (Volatility)
-1.16
Earnings Per Share
$-0.49
GPCR Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat, primarily based on intellectual property surrounding its GPCR platform and specific drug candidates like GSBR-1290, is expanding contingent on successful clinical trials and subsequent patent protection. Durability will depend on robust clinical outcomes and the ability to fend off competitive offerings.
GPCR Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
GPCR Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Phase 2b data readout for GSBR-1290 (oral GLP-1) targeting obesity/diabetes (mid-2026)
Medium-Term (6-18 months)
- •Potential strategic partnership announcements post-positive GSBR-1290 data
- •Advancement of other pipeline assets through preclinical/early clinical stages
Long-Term (18+ months)
- •Establishment of market leadership in oral GLP-1 segment
- •Broad utilization and commercialization of the GPCR-focused platform
Catalysts & Growth Drivers
Sign up free to see growth catalysts
GPCR Bull Case: What Could Go Right
- ✓
Positive and statistically significant Phase 2b data for GSBR-1290, particularly on weight loss and glucose control metrics.
- ✓
Formation of strategic partnerships or licensing agreements for GSBR-1290 or other pipeline assets.
- ✓
Any indications of positive financial updates or improved transparency regarding cash position.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Structure Therapeutics Inc (GPCR)?
As of April 12, 2026, Structure Therapeutics Inc has a DVR Score of 7.7 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Structure Therapeutics Inc?
Structure Therapeutics Inc's market capitalization is approximately $3.8B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Structure Therapeutics Inc use?
GPCR is the ticker symbol for Structure Therapeutics Inc. The company trades on the NGM.
What is the risk level for GPCR stock?
Our analysis rates Structure Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of GPCR?
Structure Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -67.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Structure Therapeutics Inc's revenue growing?
Structure Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is GPCR stock profitable?
Structure Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the GPCR DVR analysis updated?
Our AI-powered analysis of Structure Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.